{"name":"Spanish Oncology Genito-Urinary Group","slug":"spanish-oncology-genito-urinary-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Erdafitinib monotherapy","genericName":"Erdafitinib monotherapy","slug":"erdafitinib-monotherapy","indication":"Locally advanced or metastatic urothelial carcinoma with FGFR alterations","status":"phase_2"}]}],"pipeline":[{"name":"Erdafitinib monotherapy","genericName":"Erdafitinib monotherapy","slug":"erdafitinib-monotherapy","phase":"phase_2","mechanism":"Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling in cancer cells.","indications":["Locally advanced or metastatic urothelial carcinoma with FGFR alterations","Other FGFR-driven solid tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZTlOdEhER0pJNGoxMkhDblFINzhjUXZ0Tjh1aGdmSUhTQnRKUWw0YW1LdDlEazY2WkY2RnJwNklkeUV0VV9aazVPYWdpUmdleWdHRENhM0xGNk5ObVFDeHJzUXNSTEVtVnRkTDZsVlNtallhandUSHNCcTdpY2I2ZmFsdzhVQzZYVk44ODlQMjRnaW1FQWx2QVdVVnNlN0JIeWxTMWZFeU42OXNoNDNSakl4aGhJbkRkcjFr?oc=5","date":"2026-02-25","type":"pipeline","source":"Cancer Therapy Advisor","summary":"ASCO GU 2026 to Highlight the Latest Developments in Genitourinary Cancer - Cancer Therapy Advisor","headline":"ASCO GU 2026 to Highlight the Latest Developments in Genitourinary Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNSXNZTVBrTElFREVRcUpBYVduZnlSNFVSRU9fV2V2UmE5MndVdmM2dERQRy1naEIxQWoxTnR0X0c5dzh3eWlhRHNWVEVtUTFBNXFFbGZ2dDNZQTVkNGNtNmNUSjBKMzlCMHdHMi1JNDNodzRNXzlQcDIwSWotY1poNnlMRmlSdW9OS3k3QjhUbDB0eVgxVTRWVXFMVjdPWjFFUkNEak5tZ9IBrgFBVV95cUxNMmRvQ1RQSHJJdVh6TzRiclZtRFNfNmpob2tRUUhMcU00T2xabjM0cFlMMTJKUUJTVUJtVUtGM2hhX2xzMURFY3VxblA1eC1nMlk3dF9lWUZOOFVpci11U2x6andJUmlKQ05lU1VNWkJXNkFhSTZJY0Jia1dJMGtFbTgzU1lXQmllZkZCRXJuS0hTQnVGWDBSeWpjeFN5QnEtcFIwTlJSc2VkY1dyalE?oc=5","date":"2026-01-10","type":"pipeline","source":"Indian Pharma Post","summary":"AstraZeneca appoints Laura Colon as new President of Spain - Indian Pharma Post","headline":"AstraZeneca appoints Laura Colon as new President of Spain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZjdYNWNaS0FJM0puckdxODJ1MmRkRnY0cGNVUHRqWmdQZ3A4Q29NZHN4Q0NaZDJBOW1sZUNkRTUwcEpYOU5kcjhkdHl6ZEFLdFhOdk5jb0xtM2NaU0w5SE1SazI1eTBvT3VmaHFtN0tPTDM5WVc2WkpZRUpEVmdfSGtVakNWSWlBZ05YdU5UcVIzX08t?oc=5","date":"2024-08-21","type":"earnings","source":"Frontiers","summary":"E-learning pills on immunotherapy in urothelial carcinoma: The E-PIMUC program for continuing medical education - Frontiers","headline":"E-learning pills on immunotherapy in urothelial carcinoma: The E-PIMUC program for continuing medical education","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNTFhpLThvSTRhVTBUaW5KQm84b0JJMUlNb1JwRlZGbU9oTWs2TXhFdHM0TTdIX2pPREVPWE1fVGdZRTVRQVI3VzJrV3J5R2plMG1oTzk1OFN5VDdOeElEUFZFOS10akxtbTUwS3UtWWpWWGJaZ3hIenFIRXZoVXQwT24wSm1rVXQ1WmdQN0Z5aGN6Rlh3QWJxUFprcDdQNkJ0VmVmMWVRZDhnRGxCeUpOUTFyTXFYejdOcFRNcndvZmZVTXA0TldlZjFOZ29SN1ZIVXlvSXBiY2lBdw?oc=5","date":"2024-07-30","type":"patent","source":"BioSpace","summary":"Spain Pharmaceutical Market to Reach a CAGR of 5.40% during 2024-2032, Impelled by Increasing Adoption of Generic Drugs - BioSpace","headline":"Spain Pharmaceutical Market to Reach a CAGR of 5.40% during 2024-2032, Impelled by Increasing Adoption of Generic Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxOUjlocVJFZUhPc1Q1Nzh3RmxMbjd2eXpKS3dYUTN4VXAyQTNsRVhlSVJVR2l4SV84dlRnS1FFLXBtUklZNDcybUFKUlM0RkhnT29ETXJKNXFWS0VJWjJ0dVA3MlppUEJ6cU9qSEdQUUpoa0VSSER6N3BKS09UdUFXZ3FlbG1iVm5nSjVOSDZKMTZoWkZpNGpmc21kZFNWaEJCWmlNY2xGY3QtWUV6NUtlNnNENGpibWpFQ1BOVzFHOWVaZml4ZlBZLWZOZTkzc19uUjdnZkNRb25jbEJXc1hfUklWWDFkNFZwV2U0WXBlUWFraE5pZTU2TGw4RGxJaU5BNGxDcjcxX1hILVlBcEZ6dXBjeHBncnAwdmJNdFdELXJhNTFlckVuRGlCcVZuSFVvUU13Wg?oc=5","date":"2023-08-15","type":"pipeline","source":"UroToday","summary":"Exploring the Prognostic and Predictive Value of ctDNA with Signatera - Adam ElNaggar - UroToday","headline":"Exploring the Prognostic and Predictive Value of ctDNA with Signatera - Adam ElNaggar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNVk3aG9aeHB5VlRPQlNjd2NRa0lqRFd6Z01UWTJmRDRpcWg2NTRLUVhEdmlKd2c4MmpPdThFQ2gtNDdmZGVyR1pQbFE4eDJYZW5OUXlLc2xWd1RoWmtzTmR3R0xLSDNGYTF3SHd1akhGRmNFNVNYNjF0YzZkZUt5OWlfVXk2N3lIUzlmcWhJS3FwbllyMi1MRmdhd2V2eE0tVTZwSkdDZmZDQQ?oc=5","date":"2021-11-05","type":"pipeline","source":"Oncology Central","summary":"Key challenges and opportunities to advance bladder cancer care - Oncology Central","headline":"Key challenges and opportunities to advance bladder cancer care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQWExrZ29DUnJldVJMeVNLRkJBdGVNX2Q4eE9fSjBDOVp5OWp5M2R2XzhzVnRLRzhKajJxUWQ4QURUemtGTkxXbjZXaFFBUmh5aDlFM3NqWUVhYy1WeUZWaElzN1hPSTNSV0lUeHIyUWMtc01rN1hVR2p4eUlDeHlMQXVyb3lBYUZEWm9qZDBESFZvSlJocGx2cDk3RjRRRXNsMTROVXQzcw?oc=5","date":"2021-01-15","type":"pipeline","source":"Centro Nacional de Investigaciones Oncológicas - CNIO","summary":"Luis Paz-Ares and Marisol Soengas, new President and Vice-President of ASEICA - Centro Nacional de Investigaciones Oncológicas - CNIO","headline":"Luis Paz-Ares and Marisol Soengas, new President and Vice-President of ASEICA - Centro Nacional de Investigaciones Oncol","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBoS3ZGQWd4RjlqV2Z6aDNrT3htcXRERDZFOFNhUUh6WHdra1JLZDkwZ0k3QmhobWpISlU3ZDI3RWNTMmtTVWtlX2YydDZCTVdncmNXQQ?oc=5","date":"2013-06-25","type":"trial","source":"Nature","summary":"Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study - Nature","headline":"Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone me","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}